CR20250019A - Derivados novedosos de indol sulfonamida 7 sustituidos - Google Patents

Derivados novedosos de indol sulfonamida 7 sustituidos

Info

Publication number
CR20250019A
CR20250019A CR20250019A CR20250019A CR20250019A CR 20250019 A CR20250019 A CR 20250019A CR 20250019 A CR20250019 A CR 20250019A CR 20250019 A CR20250019 A CR 20250019A CR 20250019 A CR20250019 A CR 20250019A
Authority
CR
Costa Rica
Prior art keywords
novel
substituted indole
sulfonamide derivatives
indole sulfonamide
zoxn5
Prior art date
Application number
CR20250019A
Other languages
English (en)
Inventor
Emmanuel Pinard
Luca Claudio Gobbi
Wolfgang Guba
Guido Galley
Dmitry Mazunin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20250019A publication Critical patent/CR20250019A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general (I) <img alt="" src="data:image/png;base64,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 (***)
CR20250019A 2022-07-28 2023-07-26 Derivados novedosos de indol sulfonamida 7 sustituidos CR20250019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22187365 2022-07-28
PCT/EP2023/070658 WO2024023129A1 (en) 2022-07-28 2023-07-26 Novel 7-substituted indole sulfonamide derivatives

Publications (1)

Publication Number Publication Date
CR20250019A true CR20250019A (es) 2025-03-03

Family

ID=82748117

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250019A CR20250019A (es) 2022-07-28 2023-07-26 Derivados novedosos de indol sulfonamida 7 sustituidos

Country Status (17)

Country Link
EP (1) EP4562004A1 (es)
JP (1) JP2025525012A (es)
KR (1) KR20250042748A (es)
CN (1) CN119585258A (es)
AR (1) AR130024A1 (es)
AU (1) AU2023315042A1 (es)
CA (1) CA3261058A1 (es)
CL (1) CL2025000126A1 (es)
CO (1) CO2025002028A2 (es)
CR (1) CR20250019A (es)
IL (1) IL316866A (es)
MA (1) MA71601A (es)
MX (1) MX2025000875A (es)
PE (1) PE20250784A1 (es)
TW (1) TW202417430A (es)
WO (1) WO2024023129A1 (es)
ZA (1) ZA202408503B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2700773A (en) 2024-05-23 2026-03-11 Pheno Therapeutics Ltd Compounds
GB2701173A (en) 2024-05-23 2026-04-22 Pheno Therapeutics Ltd Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3584244A1 (en) * 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides
JP2024507176A (ja) * 2021-02-26 2024-02-16 エフ． ホフマン－ラ ロシュ アーゲー 新規なピリミジン－２－イルスルホンアミド誘導体

Also Published As

Publication number Publication date
PE20250784A1 (es) 2025-03-14
MX2025000875A (es) 2025-03-07
KR20250042748A (ko) 2025-03-27
MA71601A (fr) 2025-05-30
AR130024A1 (es) 2024-10-23
ZA202408503B (en) 2025-07-30
CA3261058A1 (en) 2024-02-01
CL2025000126A1 (es) 2025-05-23
JP2025525012A (ja) 2025-08-01
WO2024023129A1 (en) 2024-02-01
AU2023315042A1 (en) 2024-11-14
TW202417430A (zh) 2024-05-01
CO2025002028A2 (es) 2025-03-06
IL316866A (en) 2025-01-01
CN119585258A (zh) 2025-03-07
EP4562004A1 (en) 2025-06-04

Similar Documents

Publication Publication Date Title
CR20250019A (es) Derivados novedosos de indol sulfonamida 7 sustituidos
CR20210558A (es) Compuestos antivirales que contienen nitrilo
CR20230410A (es) Derivados novedosos de pirimidin-2-il-sulfonamida
DE602007009566D1 (de) Räumliche und spektrale kalibrierung eines multispektralen schwarzweissbildpaares
CR20250185A (es) Derivados de triazinona como inhibidores de nlrp3
PA8784201A1 (es) Derivado de 17b-ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
MA38647B1 (fr) Dérivés 11-hydroxyle d&#39;acides biliaires et leurs conjugués d&#39;acides aminés en tant que modulateurs du récepteur de farnésoïde x
CR20250018A (es) Derivados novedosos de indol sulfonamida 7 sustituidos
IL288535A (en) Superconducting interposer for optical transduction of quantum information
NO20075606L (no) Polymeriserbart fargestoff og oftalmiske linser inneholdende dette
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
BR112012033098A2 (pt) dispositivo, método e programa de processamento de informação, e, mídia de gravação
CY1106857T1 (el) Βενζαμιδια 4-(αμινομεθυλ)-πιπεριδινης ως 5ht4-ανταγωνιστες
FR3081865B1 (fr) Compositions a base de 1,1,2-trifluoroethylene et de dioxyde de carbone
NI200900202A (es) Metabolitos de derivados del (tio) - carbamoil - ciclohexano.
CY1107141T1 (el) Μεθοδος για την παρασκευη της 1-(2s,3s)-2-βενζυδρυλ-ν-(5-τριτ.-βουτυλ-2-μεθοξυβενζυλ)κινουκλιδιν-3-αμινης
DE602009000319D1 (de) Elektrofotografischer Toner
NO20075985L (no) Stabil emulsjonsforbindelse
NO20081621L (no) Tetrahydrokinoliner, syntese og intermediater
AR029942A1 (es) Compuestos derivados de 1,3-dihidro-2h-indol-2-ona, su utilizacion, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden, medicamentos constituidos por dichos compuestos y compuestos intermediarios
BR112013033824A2 (pt) inspeção ótica de recipientes
CR20250058A (es) Derivados novedosos deuterados de pirimidin-2-il sulfonamida
JP2010500432A5 (es)
CR20250545A (es) Agonistas espiromacrocíclicos de receptores de orexina 2
DK1388542T3 (da) Anvendelse af hederagenin 3-0-a-L-rhamnopyranosyl((1-&gt;2)-[beta-D-glucopyranosyl(1-&gt;4)]-a-L-arabinopyranosid eller en ekstrakt fra Pulsatillae radix indeholdende samme som et terapeutisk middel til faste tumorer